Analytical Data
-
Gene name
CD302/CLEC13A
-
简介
The CD302/CLEC13A protein emerged as a potential multifunctional C-type lectin receptor, indicating its widespread involvement in cellular processes. This protein has a potential role in endocytosis and phagocytosis and is involved in cellular clearance. CD302/CLEC13A Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD302/CLEC13A protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Alternative Names
CD302 antigen; C-type lectin domain family 13 member A; CD302; CLEC13A
-
Species
Rat
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5FVR3
-
Expression Region
D21-H165
-
Protein Length
Extracellular Domain
-
Molecular Weight
47 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD302, also known as CLEC13A, is a C-type lectin receptor that plays a significant role in the immune system, particularly in the regulation of dendritic cell functions and the modulation of immune responses. Researchers have shown that CD302 is involved in various cellular processes, including cell adhesion, migration, and pathogen recognition. Its expression is notably upregulated in inflammation and certain diseases, suggesting its potential as a therapeutic target. The study of CD302/CLEC13A recombinant proteins has also gained attention due to their possible applications in vaccine development and immune therapy, as they can enhance antigen presentation and stimulate specific immune responses. Additionally, understanding the structure and function of CD302 could provide insights into its interactions with other immune cells and its role in disease progression. As recombinant technology advances, producing CD302/CLEC13A proteins allows for in-depth studies of their biological functions, interactions, and potential as biomarkers or therapeutic agents in immune-related disorders. Overall, the ongoing research on CD302/CLEC13A recombinant proteins holds promise for unveiling novel strategies in immunotherapy and enhancing our understanding of immune regulation mechanisms.
